IMMUNOHISTOCHEMICAL STUDY OF TRANSCRIPTION FACTORS NEUROD1, PROX1, FOXM1, SOMATOSTATIN, AND CXCR4 RECEPTORS, CD38 IN GLIOBLASTOMAS TO DEVELOP NEW APPROACHES FOR THE TARGETED THERAPY
- Authors: Galkovsky B.E1, Mitrofanova L.B1, Gulyaev D.A1, Lakhina Y.S.1, Osipov Y.S1
-
Affiliations:
- Almazov National Medical Research Centre
- Issue: Vol 18, No 2 (2020)
- Pages: 44-50
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2918/article/view/113243
- DOI: https://doi.org/10.29296/24999490-2020-02-08
- ID: 113243
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
B. E Galkovsky
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
Russian Federation, St. Petersburg
L. B Mitrofanova
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
Russian Federation, St. Petersburg
D. A Gulyaev
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
Russian Federation, St. Petersburg
Y. S. Lakhina
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
Russian Federation, St. Petersburg
Y. S Osipov
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
Russian Federation, St. Petersburg
References
- Thakkar J.P., Dolecek T.A., Horbinski C., Ostrom Q.T., Lightner D.D., Barnholtz-Sloan J.S. and Villano J.L. Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014; 23 (10): 1985-96. https://doi. org/10.1158/1055-9965.EPI-14-0275. Epub 2014 Jul 22.
- Chakrabarti I., Cockburn M., Cozen W., Wang Y., Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer. 2005; 104 (12): 2798-806. https:// doi.org/10.1002/cncr.21539.
- Davis M. Glioblastoma: Overview of Disease and Treatment. Clin. J. Oncol. Nurs. 2016; 20 (5 Suppl): 2-8. https://doi. org/10.1188/16.CJON.S1.2-8.
- Tamimi A.F., Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma (Internet). Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 8. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK470003/ https://doi.org/10.15586/codon.glioblas-toma.2017.ch8
- Malmström A., Gronberg B.H., Marosi C., Stupp R., Frappaz D., Schultz H., Abacioglu U., Tavelin B., Lhermitte B., Hegi M.E. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13 (9): 916-26. https://doi.org/10.1016/S1470-2045(12)70265-6. Epub 2012 Aug 8.
- Mrugala M.M. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med. 2013; 15 (83): 221-30. http://www.discoverymedicine. com/Maciej-M-Mrugala/2013/04/25/ad-vances-and-challenges-in-the-treatment-of-glioblastoma-a-clinicians-perspective/.
- Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006; 107 (5): 1761-7. https://doi.org/10.1182/ blood-2005-08-3182.Epub 2005 Nov 3.
- Wang Z., Zhang S., Siu T., Huang S. Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor. Curr Pharm Des. 2015; 21 (10): 1268-71. https://doi.org/ 10.2174/1381612821666141211115949.
- Sun L.C., Coy D.H. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv. 2011; 8 (1): 2-10. https://doi. org/10.2174/156720111793663633
- Elsir T, Smits A., Lindström M.S., Nistér M. Transcription factor PROX1: its role in development and cancer. Cancer Metastasis Rev. 2012; 31 (3-4): 793-805. https://doi. org/10.1007/s10555-012-9390-8.
- Levy A., Blacher E., Vaknine H., Lund F.E., Stein R., Mayo L. CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/ macrophages. Neuro Oncol. 2012; 14 (8): 1037-49. https://doi.org/10.1093/neuonc/ nos121. Epub 2012 Jun 14.
- Гальковский Б.Э., Воробьева О.М., Митрофанова Л.Б. Клинико-морфологическое исследование прогностических факторов NeuroD1, HLA-DR и Ki-67 в различных типах аденом надпочечников и гипофиза Медлайн. 2017; 18: 572-90. http://www. medline.ru/public/art/tom18/art39.html
- Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T, Preibisch S., Rueden C., Saalfeld S., Schmid B., Tinevez J.Y., White D.J., Hartenstein V, Eliceiri K., Tomancak P., Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9 (7): 676-82. https://doi.org/10.1038/nmeth.2019.
- Sonikpreet A., Manna A., Schiapparelli P., Ailawadhi S., Paulus A., Rosenfeld S., Chanan-Khan A.A., Quinones-Hinojosa A. CD38-targeted therapy in glioblastoma: A step forward. J. Clin. Oncol. 2018; 36 (15): e14030. https://doi.org/10.1200/ JCO.2018.36.15_suppl.e14030
- Lohela M., Alitalo K. Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy 1st ed. Marmé D, Fusenig N, Berlin: Springer Science & Business Media. 2008; 327.
- Richardson P.J. CXCR4 and Glioblastoma Anticancer Agents Med Chem. 2016; 16 (1): 59-74. https://doi.org/10.2174/1871520 615666150824153032.
- Alvarez-Fernandez M., Medema R.H. Novel functions of FoxM1: from molecular mechanisms to cancer therapy. Front Oncol. 2013; 3: 30. https://doi.org/10.3389/ fonc.2013.00030. eCollection 2013.
- Kaemmerer D., Schindler R., Mußbach F, Dahmen U., Altendorf-Hofmann A., Dirsch O., Sänger J., Schulz S., Lupp A. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer. 2017; 17 (1): 896. https://doi.org/10.1186/s12885-017-3911-3.
- Guichet P.O., Bieche I., Teigell M., Serguera C., Rothhut B., Rigau V, Scamps F., Ripoll C., Vacher S., Taviaux S., Chevassus H., Duffau H., Mallet J., Susini A., Joubert D., Bauchet L., Hugnot J.P. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia. 2013; 61 (2): 225-39. https://doi. org/10.1002/glia.22429. Epub 2012 Oct 9.
- Vieira L. Neto, Boguszewski C.L., Araujo L.A., Bronstein M.D., Miranda PA., Musolino N.R., Naves L.A., Vilar L., Ribeiro-Oliveira A. Junior, Gadelha M.R. A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2016; 60 (4): 374-90. https://doi.org/10.1590/2359-3997000000179.
- Shenoy P.A., Kuo A., Khan N., Gorham L., Nicholson J.R., Corradini L., Vetter I., Smith M.T. The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Front Pharmacol. 2018; 9: 495. https://doi.org/10.3389/ fphar.2018.00495. ECollection 2018.
- Melpomeni F., Nicolas G.P., Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy J. Nucl. Med. 2017; 58 (Suppl 2): 61-6. https://doi.org/10.2967/ jnumed.116.186783.
- Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Genome Atlas Research Network. Cancer Cell. 2010; 17 (1): 98-110. https:// doi.org/10.1016/j.ccr.2009.12.020.
- Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013; 110 (10): 4009-14. https://doi.org/10.1073/ pnas.1219747110. Epub 2013 Feb 14.
- Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285 (21): 1182-6. https://doi.org/10.1056/ NEJM197111182852108
- Sharma A., Shiras A. Cancer stem cell-vascular endothelial cell interactions in glioblastoma. Biochem Biophys Res Commun. 2016; 473 (3): 688-92. https://doi.org/10.10Wj. bbrc.2015.12.022. Epub 2015 Dec 12.
- Plaks V, Kong N., Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015; 16 (3): 225-38. https://doi. org/10.1016/j.stem.2015.02.015.
- Brooks M.D., Sengupta R., Snyder S.C., Rubin J.B. Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche. Curr Pathobiol Rep. 2013; (2): 101-10. https://doi.org/10.1007/ s40139-013-0012-0.
- Codrici E., Enciu A.M., Popescu I.D., Mihai S., Tanase C. Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets. Stem Cells Int. 2016; 2016: 5728438. https://doi. org/10.1155/2016/5728438. Epub 2016 Feb 10.
- Osswald M., Jung E., Weil S., Blaes J., Solecki G., Kurz F.T., Heiland S., Huber P.E., Wick W., Winkler F. P08.31 A perivascular niche for progression and resistance in glioblastoma. Neuro Oncol. 2016; 18 (Suppl 4): iv48. Published online 2016 Sep 21. https:// doi.org/10.1093/neuonc/now188.164
- Seano G. Targeting the perivascular niche in brain tumors. Curr Opin Oncol. 2018; (1): 54-60. https://doi.org/10.1097/ CCO.0000000000000417.
- Lee S.Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016; (3): 198-210. https://doi.org/10.10Wj. gendis.2016.04.007. eCollection 2016 Sep.
Supplementary files
![](/img/style/loading.gif)